Nano-ropinirole for the management of Parkinsonism: blood–brain pharmacokinetics and carrier localization. (June 2015)

• Record Type: Journal Article
• Authors: Mustafa, Gulam; Ahuja, Alka; Al Rohaimi, Abdulmohsen H; Muslim, Shahnawaz; Hassan, Allam A; Baboota, Sanjula; Ali, Javed
• Is Part Of: Expert review of neurotherapeutics. Volume 15:Number 6(2015)
• Page Start: 695
• Page End: 710
• Publication Date: 2015-06
• Subjects: Neuropharmacology -- Periodicals; 615.7805
• DOI: 10.1586/14737175.2015.1036743
• Languages: English
• ISSNs: 1473-7175

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Aim: The aim of this study was to investigate the brain targeting potential of chitosan-coated oil in water nanoemulsions (CSNE<sup>ROP</sup>) delivered intranasally in haloperidol-induced Parkinson's disease rat models. Methods: Chitosan-coated nanoemulsion (CSNE<sup>ROP</sup>) was developed through aqueous titration followed by a high pressure homogenization method. Results: Gamma-scintigraphy study showed a significantly high mucoadhesive potential of CSNE<sup>ROP</sup> and least for conventional and homogenized formulations. Confocal study showed deep localization of formulations in the brain confirming the permeation potential of CSNE<sup>ROP</sup>. Pharmacokinetic results of CSNE<sup>ROP</sup> in <italic>Wistar rat</italic> brain and plasma showed a significantly high (p** < 0.005) AUC<sub>0→24</sub> and amplified C<sub>max</sub> over <italic>i.v</italic> treatment group. Neurobehavioral activity (rotarod and swim tests) and biochemical parameters (glutathion, TBARS and SOD) corroborated well with the pharmacokinetic results. The order of dopamine recovery in haloperidol-induced <italic>Wistar rats</italic> was found to be <sup>i.n</sup>CSNE<sub>ROP</sub> group><sup>i.n</sup>Soln<sub>ROP</sub> group><sup>i.v</sup>Soln<sub>ROP</sub> group>haloperidol group. Conclusions: Finally, the investigation demonstrated that intranasal delivery of mucoadhesive nanocarrier might play as a potential candidate in the management of Parkinson's disease and related brain disorders.</p> </abstract>